• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    IM Cannabis Provides Corporate Updates

    7/1/25 8:00:00 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $IMCC alert in real time by email

    TORONTO and GLIL YAM, Israel, July 1, 2025 /PRNewswire/ -- IM Cannabis Corp. (NASDAQ:IMCC) (the "Company", "IM Cannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, today announced the following corproate updates.

    IM Cannabis Logo

     

    As previously reported on April 11, 2025, the Company received a deficiency letter (the "Nasdaq Letter") on April 9, 2025 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (the "Nasdaq") notifying the Company that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires the Company to maintain a minimum of $2,500,000 in stockholders' equity for continued listing on the Nasdaq Capital Market (the "Stockholders' Equity Requirement"), nor is it in compliance with either of the alternative listing standards, market value of listed securities of at least $35 million or net income of $500,000 from continuing operations in the most recently completed fiscal year, or in two of the three most recently completed fiscal years.

    On May 23, 2025, the Company submitted to Nasdaq its plan to regain compliance with Nasdaq Listing Rule 5550(b)(1) (the "Compliance Plan"). Based on the Compliance Plan, on June 25, 2025, Nasdaq notified the Company that it had determined to grant the Company an extension of time to regain compliance with the Stockholders' Equity Requirement until October 6, 2025. If the Company fails to evidence compliance by the required deadline, the Company may be subject to delisting. At that time, the Company may appeal the Nasdaq staff's determination to a Hearings Panel.

    The Company intends to take all reasonable measures available to regain compliance with the Nasdaq Listing Rules and remain listed on Nasdaq. However, there can be no assurance that the Company will ultimately regain compliance with all applicable requirements for continued listing.

    Neither the Nasdaq Letter nor the Company's current noncompliance have an immediate effect on the listing or trading of the Company's common shares, which will continue to trade on the Nasdaq Capital Market under the symbol "IMCC".

    About IM Cannabis Corp.

    IMC (NASDAQ:IMCC) is an international cannabis company dedicated to providing medical cannabis products to medical patients in Israel and Germany, two key players in the global cannabis industry. The Company leverages a transnational ecosystem powered by a unique data-driven approach and a globally sourced product supply chain. With an unwavering commitment to responsible growth and adherence to the strictest regulatory environments, the Company strives to amplify its commercial and brand power to become a leading global provider of high-quality cannabis.

    The IMC ecosystem operates in Israel through its subsidiaries, which imports and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of IMC products throughout the entire value chain. In Germany, the IMC ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains forward-looking information or forward-looking statements under applicable Canadian and United States securities laws, including the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws (collectively, "forward-looking statements"). All information that addresses activities or developments that the Company expects to occur in the future are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "believe", "plan", "estimate", "expect", "likely" and "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made and may prove to be incorrect..

    Forward-looking statements are based on assumptions that may prove to be incorrect, including but not limited to: the Company's ability to regain compliance with Nasdaq's continued listing requirements, and timing and effect thereof.

    The above lists of forward-looking statements, assumptions and their implications are not exhaustive and are based on the currect expecations of the management of the Company only. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated or implied by such forward-looking statements due to a number of factors and risks. These include:  the Compnay may not be able to complete a financing transaction on favourable terms, in a timely manner or at all;  the failure of the Company to comply with applicable regulatory requirements in a highly regulated industry; unexpected changes in governmental policies and regulations in the jurisdictions in which the Company operates; the Company's inability to regain compliance to meet the listing requirements of the Nasdaq; any unexpected failure to maintain in good standing or renew its licenses; the ability of the Company and Focus Medical Herbs Ltd. (collectively, the "Group") to deliver on their sales commitments or growth objectives; the reliance of the Group on third-party supply agreements to provide sufficient quantities of medical cannabis to fulfil the Group's obligations;the Group's possible exposure to liability, the perceived level of risk related thereto, and the anticipated results of any litigation or other similar disputes or legal proceedings involving the Group; the impact of increasing competition; any lack of merger and acquisition opportunities; adverse market conditions; the inherent uncertainty of production quantities, qualities and cost estimates and the potential for unexpected costs and expenses; risks of product liability and other safety-related liability from the usage of the Group's cannabis products; supply chain constraints; reliance on key personnel; the risk of defaulting on existing debt; risks surrounding war, conflict and civil unrest in Eastern Europe and the Middle East, including the impact of the multi front war Israel is facing on the Company, its operations and the medical cannabis industry in Israel; risks associated with the Company focusing on the Israel and Germany markets; the Company's inability to realize upon the stated efficiencies and synergies of the Company as a global organization with domestic expertise in Israel and Germany; the Company's inability to realize upon its retail presence, distribution capabilities and data-driven insights; and the risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual report on Form 20-F dated March 31, 2025, which is available on the Company's issuer profile on SEDAR+ at www.sedarplus.ca and Edgar at www.sec.gov/edgar. Any forward-looking statement included in this press release is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company does not undertake any obligation to update forward-looking statements except as required by applicable securities laws. Investors should not place undue reliance on forward-looking statements. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement.

    Company Contact:

    Oren Shuster, CEO

    IM Cannabis Corp.

    +972-77-3603504

    [email protected]

    Logo: https://mma.prnewswire.com/media/1742228/4630892/IM_Cannabis_Logo.jpg

    Cision View original content:https://www.prnewswire.com/news-releases/im-cannabis-provides-corporate-updates-302495605.html

    SOURCE IM Cannabis Corp.

    Get the next $IMCC alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $IMCC

    DatePrice TargetRatingAnalyst
    10/5/2021$8.00Buy
    ROTH Capital
    7/14/2021Buy
    Desjardins
    7/14/2021$10.50Buy
    Desjardins
    More analyst ratings

    $IMCC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ROTH Capital initiated coverage on IM Cannabis with a new price target

      ROTH Capital initiated coverage of IM Cannabis with a rating of Buy and set a new price target of $8.00

      10/5/21 7:57:00 AM ET
      $IMCC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Desjardins initiated coverage on IMC Mortgage Co

      Desjardins initiated coverage of IMC Mortgage Co with a rating of Buy

      7/14/21 8:40:32 AM ET
      $IMCC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Desjardins initiated coverage on IM Cannabis with a new price target

      Desjardins initiated coverage of IM Cannabis with a rating of Buy and set a new price target of $10.50

      7/14/21 7:01:53 AM ET
      $IMCC
      Medicinal Chemicals and Botanical Products
      Health Care

    $IMCC
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $IMCC
    SEC Filings

    See more
    • IM Cannabis Provides Corporate Updates

      TORONTO and GLIL YAM, Israel, July 1, 2025 /PRNewswire/ -- IM Cannabis Corp. (NASDAQ:IMCC) (the "Company", "IM Cannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, today announced the following corproate updates.   As previously reported on April 11, 2025, the Company received a deficiency letter (the "Nasdaq Letter") on April 9, 2025 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (the "Nasdaq") notifying the Company that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires the Company to maintain a minimum of $2,500,000 in stockholders' equity for continued listing on the Nasdaq Capital Market (the

      7/1/25 8:00:00 AM ET
      $IMCC
      Medicinal Chemicals and Botanical Products
      Health Care
    • IM Cannabis Announces Plans to Voluntarily Delist from the Canadian Securities Exchange

      TORONTO and GLIL YAM, Israel, May 28, 2025 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ:IMCC) (CSE:IMCC), an international medical cannabis company, announces that it has applied for a voluntary delisting of its common shares ("Shares") from the Canadian Securities Exchange (the "CSE"). The delisting from the CSE will not affect the Company's listing on NASDAQ and its Shares will continue trading on the NASDAQ under the symbol "IMCC". The Company is entertaining potential transactions that, if completed while the Company is listed on the CSE, would require the Company to incur unnecessary burdensome costs, approvals and delay. The Company believes that the trading volu

      5/28/25 8:00:00 AM ET
      $IMCC
      Medicinal Chemicals and Botanical Products
      Health Care
    • IM Cannabis Provides Corporate Updates

      THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO and GLIL YAM, Israel, May 27, 2025 /PRNewswire/ -- IM Cannabis Corp. ("IM Cannabis" or the "Company") (NASDAQ:IMCC) (CSE:IMCC), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce the following corporate updates. Meeting Results Further to its press releases dated Aprill 11, 2025 (the "April 11 Release") and May 7, 2025 (the "May 7 Release"), the Company is pleased to announce results of its annual general and special meeting, held on Friday, May 23, 2025 (the "Meeting"

      5/27/25 8:00:00 AM ET
      $IMCC
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 6-K filed by IM Cannabis Corp.

      6-K - IM Cannabis Corp. (0001792030) (Filer)

      7/1/25 8:57:24 AM ET
      $IMCC
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form F-3 filed by IM Cannabis Corp.

      F-3 - IM Cannabis Corp. (0001792030) (Filer)

      6/26/25 4:05:52 PM ET
      $IMCC
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 6-K filed by IM Cannabis Corp.

      6-K - IM Cannabis Corp. (0001792030) (Filer)

      5/28/25 8:14:12 AM ET
      $IMCC
      Medicinal Chemicals and Botanical Products
      Health Care

    $IMCC
    Leadership Updates

    Live Leadership Updates

    See more
    • IM Cannabis Announces Appointment of Shmulik Arbel to Board of Directors

      TORONTO and GLIL YAM, Israel, Sept. 11, 2024 /PRNewswire/ --  IM Cannabis Corp. ("IMC" or the "Company") (NASDAQ:IMCC) (CSE:IMCC), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that Mr. Shmulik Arbel has been appointed to the Company's board of directors (the "Board") effective September 9, 2024. Mr. Arbel brings a wealth of experience in strategic plans that drive profitability, as well as, finance and corporate governance, further strengthening the company's commitment to driving growth while focusing on sustainable profitability. "We are thrilled to welcome Shmulik to our Board of Directors," said Oren Shuster, Chief Executive Officer of

      9/11/24 8:30:00 AM ET
      $IMCC
      Medicinal Chemicals and Botanical Products
      Health Care
    • IM Cannabis Announces the appointment of Uri Birenberg as Chief Financial Officer

      TORONTO and GLIL YAM, Israel, Oct. 10, 2023 /PRNewswire/ -- IM Cannabis Corp. (CSE:IMCC) (NASDAQ:IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that Uri Birenberg will join the company's leadership team as Chief Financial Officer effective October 10, 2023.  This appointment strengthens IMC's financial leadership and strategic direction for achieving sustainable profitability. "We're delighted to welcome Uri as our new Chief Financial Officer at IMC. His impressive track record and extensive experience with large scale international organizations, as well as with startups, make him an outstandin

      10/10/23 7:00:00 AM ET
      $IMCC
      Medicinal Chemicals and Botanical Products
      Health Care
    • IM Cannabis Corp. Appoints Rinat Efrima as New Chief Executive Officer of IMC Holdings, the Company's Israeli Subsidiary

      Oren Shuster remains Chief Executive Officer and Director of IM Cannabis Corp.; other managerial changes include the promotion of Yael Harrosh to Chief Legal and Operations Officer of IM Cannabis Corp.TORONTO, ON and GLIL YAM, ISRAEL / ACCESSWIRE / January 13, 2022 / IM Cannabis Corp. (the "Company" or "IM Cannabis") (CSE:IMCC)(NASDAQ:IMCC), a leading medical and adult-use recreational cannabis company with operations in Israel, Canada, and Germany today announced the appointment of Rinat Efrima as the new Chief Executive Officer of IMC Holdings Ltd. ("IMC Holdings"), the Company's wholly-owned Israeli subsidiary. Ms. Efrima will join the Company in the first quarter of 2022. In addition, Ya

      1/13/22 8:00:00 AM ET
      $IMCC
      Medicinal Chemicals and Botanical Products
      Health Care

    $IMCC
    Financials

    Live finance-specific insights

    See more
    • IM Cannabis Reports First Quarter Financial Results

      IMC Delivers Net Profit and 87% Gross Margin Improvement in Q1, Reflecting Strategic and Operational Progress TORONTO and GLIL YAM, Israel, May 15, 2025 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ:IMCC) (CSE:IMCC), an international medical cannabis company, announced its financial results today for the first quarter ended March 31, 2025. All amounts are reported in Canadian dollars and compared to the quarter ended March 31, 2024, unless otherwise stated. IMC also announces the intention to complete a non-brokered private placement of secured debentures. Q1 2025 Financial Highlights Net profit of $175K94% Gross profit increase vs. Q1 2024 of $3.5M vs. $1.8M and 29% Gr

      5/15/25 8:00:00 AM ET
      $IMCC
      Medicinal Chemicals and Botanical Products
      Health Care
    • IM Cannabis to Report First Quarter 2025 Financial Results on Thursday, May 15th at 9:00am ET

      TORONTO and GLIL YAM, Israel, May 6, 2025 /PRNewswire/ -- IM Cannabis Corp. (CSE:IMCC) (NASDAQ:IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, will report operational and financial results for the first quarter 2025 ended March 31, 2025, on Thursday, May 15, 2025, before the market opens.     The Company will host a zoom web conference on the same day at 9:00am ET to discuss the results, followed by a question-and-answer session for the investment community. Investors are invited to register by clicking here. All relevant information will be sent upon registration. If you are unable to join us live, a recording of the

      5/6/25 7:00:00 AM ET
      $IMCC
      Medicinal Chemicals and Botanical Products
      Health Care
    • IM Cannabis Reports Fourth Quarter and Full Year 2024 Financial Results

      Q4 2024 Caps a Year of Strategic and Operational Improvements for IMC with 25% Revenue Growth, 42% decrease in Operating Expenses, and $0.5M Adjusted EBITDA Profit TORONTO and GLIL YAM, Israel, March 31, 2025 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ:IMCC) (CSE:IMCC), an international medical cannabis company, is pleased to announce its financial results for the fourth quarter and year ended December 31, 2024. Unless otherwise stated, all amounts are reported in Canadian dollars and are compared to the quarter ended December 31, 2023. The Company's audited consolidated financial statements for the fiscal years ended December 31, 2024 and 2023 and accompanying manage

      3/31/25 8:39:00 AM ET
      $IMCC
      Medicinal Chemicals and Botanical Products
      Health Care

    $IMCC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by IM Cannabis Corp.

      SC 13G - IM Cannabis Corp. (0001792030) (Subject)

      2/21/23 10:56:41 AM ET
      $IMCC
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13D/A filed by IM Cannabis Corp. (Amendment)

      SC 13D/A - IM Cannabis Corp. (0001792030) (Subject)

      2/8/23 1:29:15 PM ET
      $IMCC
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by IM Cannabis Corp. (Amendment)

      SC 13G/A - IM Cannabis Corp. (0001792030) (Subject)

      2/2/23 10:38:01 AM ET
      $IMCC
      Medicinal Chemicals and Botanical Products
      Health Care